(2S)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-N-cyclopropyl-4-methylidenepyrrolidine-2-carboxamide | 1268819-46-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (2S)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-N-cyclopropyl-4-methylidenepyrrolidine-2-carboxamide
• CAS: 1268819-46-0
• 化学式: C₁₉H₂₉N₃O₄
• 分子量: 363.457
• InChiKey: YDHCDKWXGWFEAE-WBVHZDCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  90
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-BOC-4-亚甲基-L-脯氨酸甲酯 在 N-甲基吗啉 、 水 、 氯甲酸乙酯 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 37.5h， 生成 (2S)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-N-cyclopropyl-4-methylidenepyrrolidine-2-carboxamide
  参考文献：
  名称：

  Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors

  摘要：

  The synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives are reported. The antibacterial activities of these derivatives were evaluated to discover SAR at P-1' and P-3' positions, and most of these derivatives exhibit better in vitro antibacterial activity than existing drugs against drug-resistant clinical isolates including MRSA, PRSP, and Haemophilus influenzae. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.102

文献信息

• Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors
  作者：Wei Shi、Haikun Ma、Yuejiao Duan、Kelly Aubart、Yuhong Fang、Rimma Zonis、Liping Yang、Wenhao Hu

  DOI：10.1016/j.bmcl.2010.11.102

  日期：2011.2

  The synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives are reported. The antibacterial activities of these derivatives were evaluated to discover SAR at P-1' and P-3' positions, and most of these derivatives exhibit better in vitro antibacterial activity than existing drugs against drug-resistant clinical isolates including MRSA, PRSP, and Haemophilus influenzae. (C) 2010 Elsevier Ltd. All rights reserved.